Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML
    Meeting Abstract

    Stone, R. M.; Wang, E. S.; Goldberg, A. D.; Sweet, K. L.; Fathi, A. T.; Liu, H.; Messahel, B.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Shah, B. D.; Bishop, M. R.; Oluwole, O. O.; Logan, A.; Baer, M. R.; Donnellan, W. B.; Carr-O'Dwyer, K. M.; Holmes, H.; Arellano, M. L.; Ghobadi, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study
    Meeting Abstract

    Roboz, G. J.; Dinardo, C. D.; Stein, E. M.; de Botton, S.; Mims, A. S.; Prince, G. T.; Altman, J. K.; Arellano, M. L.; Erba, H. P.; Pollyea, D. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL
    Meeting Abstract

    Perica, K.; Flynn, J.; Curran, K. J.; Wang, X.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; Gonen, M.; Riviere, I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Minami, Y.; Allepuz, A.; Polydoros, F.; Bédoucha, V.; Aimone, P.; Réa, D.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio
    Meeting Abstract

    Levis, M. J.; Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Dinardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Martinelli, G.; Patel, P. A.; Raffoux, E.; Tan, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent
    Meeting Abstract

    Adusumilli, P. S.; Zauderer, M. G.; Rusch, V. W.; O'Cearbhaill, R.; Zhu, A.; Ngai, D.; McGee, E.; Chintala, N.; Messinger, J.; Cheema, W.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer
    Meeting Abstract

    Toska, E.; Xu, G.; Chhangawala, S.; Cocco, E.; Razavi, P.; Otto, J.; Cai, Y.; Chan, C.; D'Avino, D. R.; Collings, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save